Tarek M Mekhail

Summary

Affiliation: Cleveland Clinic Foundation
Country: USA

Publications

  1. ncbi Phase 1 trial of Anvirzel in patients with refractory solid tumors
    Tarek Mekhail
    Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, 9500 Euclid Ave, Cleveland, OH 44195, USA
    Invest New Drugs 24:423-7. 2006
  2. ncbi Phase II study of gemcitabine and cisplatin in patients with previously untreated extensive stage small cell lung cancer: Southwest Oncology Group Study 9718
    Paul J Hesketh
    Caritas St Elizabeth s Medical Center of Boston, Boston, Massachusetts 02135, USA
    J Thorac Oncol 2:440-4. 2007
  3. doi Utility of positron emission tomography compared with mediastinoscopy for delineating involved lymph nodes in stage III lung cancer: insights for radiotherapy planning from a surgical cohort
    Gregory M M Videtic
    Department of Radiation Oncology, Cleveland Clinic Foundation, Cleveland, OH, USA
    Int J Radiat Oncol Biol Phys 72:702-6. 2008
  4. ncbi Acanthosis nigricans with endometrial carcinoma: case report and review of the literature
    Tarek M Mekhail
    Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Gynecol Oncol 84:332-4. 2002
  5. ncbi Renal cell carcinoma (RCC) and telomerase activity: relationship to stage
    Tarek M Mekhail
    Expermental Therapeutics, Taussig Cancer Center, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Urol Oncol 21:424-30. 2003
  6. ncbi Tubulin interacting agents: novel taxanes and epothilones
    Neeraj R Agrawal
    Experimental Therapeutics, Taussig Cancer Center, The Cleveland Clinic Foundation, R35, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Curr Oncol Rep 5:89-98. 2003
  7. ncbi Phase I trial of weekly docetaxel and gemcitabine in patients with refractory malignancies
    Tarek Mekhail
    Experimental Therapeutics Department, Taussig Cancer Center, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Cancer 97:170-8. 2003
  8. ncbi Paclitaxel in cancer therapy
    Tarek M Mekhail
    Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Expert Opin Pharmacother 3:755-66. 2002
  9. doi Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy
    Ali Reza Golshayan
    Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA
    J Clin Oncol 27:235-41. 2009
  10. doi Gender, race, and survival: a study in non-small-cell lung cancer brain metastases patients utilizing the radiation therapy oncology group recursive partitioning analysis classification
    Gregory M M Videtic
    Department of Radiation Oncology, Taussig Cancer Institute, The Cleveland Clinic, Cleveland, OH 44195, USA
    Int J Radiat Oncol Biol Phys 75:1141-7. 2009

Detail Information

Publications18

  1. ncbi Phase 1 trial of Anvirzel in patients with refractory solid tumors
    Tarek Mekhail
    Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, 9500 Euclid Ave, Cleveland, OH 44195, USA
    Invest New Drugs 24:423-7. 2006
    ..No objective anti-tumor responses were seen. Anvirzel can be safely administered at doses up to 1.2 ml/m2/day, with the amount administered intramuscularly limited by volume. The recommended phase II dose level is 0.8 ml/m2/day...
  2. ncbi Phase II study of gemcitabine and cisplatin in patients with previously untreated extensive stage small cell lung cancer: Southwest Oncology Group Study 9718
    Paul J Hesketh
    Caritas St Elizabeth s Medical Center of Boston, Boston, Massachusetts 02135, USA
    J Thorac Oncol 2:440-4. 2007
    ..This phase II study (S9718) evaluated the antineoplastic activity and tolerability of the combination of gemcitabine and cisplatin in previously untreated patients with extensive stage small cell lung cancer (ES-SCLC)...
  3. doi Utility of positron emission tomography compared with mediastinoscopy for delineating involved lymph nodes in stage III lung cancer: insights for radiotherapy planning from a surgical cohort
    Gregory M M Videtic
    Department of Radiation Oncology, Cleveland Clinic Foundation, Cleveland, OH, USA
    Int J Radiat Oncol Biol Phys 72:702-6. 2008
    ..We used the results of mediastinoscopy from a Stage III NSCLC cohort to assess the reliability of positron emission tomography (PET) scans at identifying involved mediastinal lymph nodes (MLN) when used during radiotherapy planning...
  4. ncbi Acanthosis nigricans with endometrial carcinoma: case report and review of the literature
    Tarek M Mekhail
    Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Gynecol Oncol 84:332-4. 2002
    ..Only five cases of endometrial carcinoma associated with acanthosis nigricans and/or tripe palms have been reported in the literature...
  5. ncbi Renal cell carcinoma (RCC) and telomerase activity: relationship to stage
    Tarek M Mekhail
    Expermental Therapeutics, Taussig Cancer Center, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Urol Oncol 21:424-30. 2003
    ..In patients with advanced disease, there is a high incidence of telomerase positivity was found, within this limited sample, however, no correlation with survival was found...
  6. ncbi Tubulin interacting agents: novel taxanes and epothilones
    Neeraj R Agrawal
    Experimental Therapeutics, Taussig Cancer Center, The Cleveland Clinic Foundation, R35, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Curr Oncol Rep 5:89-98. 2003
    ..This article describes a variety of promising novel taxanes and epothilones with similar mechanisms of action that are in various states of preclinical and clinical development...
  7. ncbi Phase I trial of weekly docetaxel and gemcitabine in patients with refractory malignancies
    Tarek Mekhail
    Experimental Therapeutics Department, Taussig Cancer Center, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Cancer 97:170-8. 2003
    ....
  8. ncbi Paclitaxel in cancer therapy
    Tarek M Mekhail
    Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Expert Opin Pharmacother 3:755-66. 2002
    ..Paclitaxel is also active against AIDS-associated Kaposi's sarcoma...
  9. doi Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy
    Ali Reza Golshayan
    Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA
    J Clin Oncol 27:235-41. 2009
    ..The utility of vascular endothelial growth factor (VEGF)-targeted therapy in patients with this disease is unknown...
  10. doi Gender, race, and survival: a study in non-small-cell lung cancer brain metastases patients utilizing the radiation therapy oncology group recursive partitioning analysis classification
    Gregory M M Videtic
    Department of Radiation Oncology, Taussig Cancer Institute, The Cleveland Clinic, Cleveland, OH 44195, USA
    Int J Radiat Oncol Biol Phys 75:1141-7. 2009
    ....
  11. ncbi Phase II study of lenalidomide in patients with metastatic renal cell carcinoma
    Toni K Choueiri
    Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, USA
    Cancer 107:2609-16. 2006
    ..A Phase II, open-label study of LEN in patients with metastatic renal cell carcinoma (RCC) was conducted to determine its safety and clinical activity...
  12. doi Winning the battle, losing the war: the noncurative "curative" resection for stage I adenocarcinoma of the lung
    Sudish C Murthy
    Department of Thoracic and Cardiovascular Surgery, Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH 44195, USA
    Ann Thorac Surg 90:1067-74. 2010
    ..Therefore, this study characterizes cancer recurrence and its risks, assesses survival after recurrence, and contextualizes overall survival and its risks...
  13. ncbi Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma
    Tarek M Mekhail
    Taussig Cancer Center, The Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195, USA
    J Clin Oncol 23:832-41. 2005
    ..To validate the Motzer et al prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma (RCC) and to identify additional independent prognostic factors...
  14. doi Combinations of DNA methyltransferase and histone deacetylase inhibitors induce DNA damage in small cell lung cancer cells: correlation of resistance with IFN-stimulated gene expression
    Wioleta Luszczek
    Hematology Oncology Research, Taussig Cancer Institute, The Cleveland Clinic, 9500 Euclid Avenue R40, Cleveland, OH 44195, USA
    Mol Cancer Ther 9:2309-21. 2010
    ....
  15. ncbi Phenoxodiol: isoflavone analog with antineoplastic activity
    Toni K Choueiri
    Department of Hematology and Medical Oncology, Taussig Cancer Center, The Cleveland Clinic Foundation, 9500 Euclid Avenue, R 35, Cleveland, OH 44195, USA
    Curr Oncol Rep 8:104-7. 2006
    ..Hormone-refractory prostate cancer is another promising area in which phenoxodiol is being actively tested. Studies are ongoing to define the optimal use of this novel anticancer agent...
  16. ncbi F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma
    Navneet S Majhail
    Department of Internal Medicine, Cleveland Clinic Foundation, OH 44195, USA
    J Clin Oncol 21:3995-4000. 2003
    ..We conducted a study to evaluate the role of F-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) in the detection of distant metastases from renal cell carcinoma (RCC).Materials and..
  17. ncbi Validation of the RTOG recursive partitioning analysis (RPA) classification for small-cell lung cancer-only brain metastases
    Gregory M M Videtic
    Department of Radiation Oncology, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Int J Radiat Oncol Biol Phys 67:240-3. 2007
    ..Clinical trials for patients with brain metastases generally exclude small-cell lung cancer (SCLC) cases. We hypothesize that the RPA classes are valid in the setting of SCLC brain metastases...
  18. ncbi Malignant acanthosis nigricans, tripe palms and the sign of Leser-Tre'lat, a hint to the diagnosis of early stage ovarian cancer: a case report and review of the literature
    Mehdi M Kebria
    Department of Obstetrics and Gynecology, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Gynecol Oncol 101:353-5. 2006
    ..We are reporting the first case of ovarian cancer in association with three coexisting cutaneous paraneoplastic dermatosis...